Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Single Centre, Open Label, Proof of Concept Study Concerning Efficacy of the Novel Intravenous Contrast Agent SN132D in Patients With Suspected Endometriosis.

NCT05664828 is registered in ClinicalTrials.gov with Spago Nanomedical AB as lead sponsor.

NCT NCT05664828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05664828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Single Centre, Open Label, Proof of Concept Study Concerning Efficacy of the Novel Intravenous Contrast Agent SN132D in Patients With Suspected Endometriosis.
Lead sponsor
Spago Nanomedical AB
Phase
Phase 2
Overall status
Completed
Start date
November 17, 2022
Completion date
September 12, 2023
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis